ABSTRACT
Objective:To investigate the status of social alienation in maintenance hemodialysis (MHD) patients, and analyze its correlation with self disclosure and social support.Methods::From May 2019 to March 2021, 156 MHD patients admitted to Nanyang Central Hospital were selected as the research objects by using convenient sampling method. A cross-sectional survey was conducted by using general information questionnaire, general alienation scale, pain disclosure index scale and social support scale.Results:A total of 176 questionnaires were issued, with an effective recovery rate of 88.64%(156/176). The social alienation score of 156 patients with MHD was (41.57±4.89) points, which was at the upper-middle level and negatively correlated with the total scores of the Distress Disclosure Index and the Perceived Social Support Scale ( r=-0.526, -0.284, all P<0.01). The results of multiple linear regression analysis showed that age, educational level, and per capita monthly household income were the main factors affecting social alienation ( β=0.199, -0.361, -0.290, all P<0.01). After controlling for the above factors, self disclosure and social support independently explained the variance of social alienation in MHD patients increased by 20.2% ( β=-0.440, -0.200, all P<0.01). Conclusions:MHD patients have a high sense of social alienation. Medical staff should pay attention to patients who are older, less educated, and have low family income. Self disclosure and social support are modifiable variables, so medical staff can reduce their social alienation and improve the quality of life by training patients on self disclosure and improving the level of social support.
ABSTRACT
@#Objective To investigate the relationship of serum levels of macrophage migration inhibitory factor (MIF), matrix metallo-proteinase-9 (MMP-9), hypersensitive C-reactive protein (hs-CRP) with the severity of acute cerebral infarction (ACI). Methods 101 pa-tients with ACI were envolved and divided into 3 groups according to the scores of National Institute of Health Stroke Scale (NIHSS):mild group (group A, n=38, NIHSS score<4), moderate group (group B, n=36, NIHSS score 4-15) and severe group (group C, n=27, NIHSS score>15). Meanwhile, 44 non-ACI inpatients with atherosclerosis were included as control group (group D). Their serum MIF and MMP-9 were detected with ELISA, and hs-CRP with immunoturbidimety. Results The levels of serum MIF, MMP-9 and hs-CRP ranged from more to less as groups C, B, A and D (P<0.05). There was positive correlation of MIF with MMP-9 (r=0.301, P<0.01) and hs-CRP (r=0.309, P<0.001). Conclusion Serum MIF, MMP-9 and hs-CRP levels increased with the severity in ACI patients, which may be prediction of athero-sclerotic plaque instability.
ABSTRACT
ObjectiveTo investigate the risk factors related with the prognosis of patients with acute cerebral infarction after intravenous thrombolysis by alteplase in 90 days.MethodsForty patients with acute cerebral infarction treated by intravenous thrombolysis with aheplase were selected and assigned into good outcome group [modified Rankin scale (mRS) 0-1 score] and poor outcome group (mRS 2-6 scores) according to mRS at 90 days.The risk factors were compared between two groups.ResultsPoor outcome group(22 cases) comparing with good outcome group (18 cases),the values of age[ (64.64±11.30) years vs.(58.94±10.47) years ],onset to therapy time(OTT) [(376.73±316.32)min vs.( 176.00±59.74) min],National Institutes of Health stroke scale (NIHSS) score before thrombolysis [ ( 16.73±8.46)scores vs. (11.22±5.20) scores],maximum of systolic blood pressure (SBPmax) in the first 24 hours after thrombolysis[ ( 186.59±24.79 )mm Hg ( 1 mm Hg =0.133 kPa) vs.( 169.00±23.04) mm Hg] and systolic blood pressure variability (SBPV)[(17.11±3.90) mm Hg vs.(13.33±4.97) mm Hg] had significant differences (P＜ 0.05).ConclusionThe values ofage,OTT,NIHSS score before thrombolysis,SBPmax and SBPV in the first 24 hours after thrombolysis are related with the prognosis of patients with acute cerebral infarction after intravenous thrombolysis by altcplase in 90 days.